1. Home
  2. DRUG vs CGBD Comparison

DRUG vs CGBD Comparison

Compare DRUG & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$78.45

Market Cap

778.4M

Sector

Health Care

ML Signal

HOLD

CGBD

Carlyle Secured Lending Inc.

HOLD

Current Price

$11.35

Market Cap

768.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRUG
CGBD
Founded
2019
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
778.4M
768.5M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
DRUG
CGBD
Price
$78.45
$11.35
Analyst Decision
Strong Buy
Hold
Analyst Count
6
8
Target Price
$129.25
$12.92
AVG Volume (30 Days)
176.6K
589.5K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
14.42%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$3.74
Revenue Next Year
N/A
$1.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.00
$9.95
52 Week High
$123.75
$14.02

Technical Indicators

Market Signals
Indicator
DRUG
CGBD
Relative Strength Index (RSI) 52.92 63.35
Support Level $76.54 $10.53
Resistance Level $83.65 $11.47
Average True Range (ATR) 3.86 0.26
MACD -0.01 0.06
Stochastic Oscillator 37.03 86.13

Price Performance

Historical Comparison
DRUG
CGBD

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

Share on Social Networks: